Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

By B. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, Karin D. Berg, K. Murphy, T. Dauses, J. Allebach, D. Small. Blood, 2004

679 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/3103a60efe66d8639ea7ebd8f9373d1a0f8636e4

Citations in the corpus

• A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “Median d from diagnosis to trial entry (range) 21 (6-166)”
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. (2005, neutral): “Median platelet count, 1000/ L (range) 30 (1-619)”